Gemfibrozil
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Gemfibrozil: From Dyslipidemia (Fibrate Class) to Rheumatoid Arthritis
One-Sentence Summary
Gemfibrozil is a classic fibrate-class PPAR-α agonist used internationally for hypertriglyceridemia and mixed dyslipidemia (it holds no current Taiwan marketing authorization). The TxGNN model predicts it may be effective for Rheumatoid Arthritis, but currently only 0 clinical trials and 4 publications (mostly case reports and indirect animal models) support this direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not TFDA-approved in Taiwan (0 licenses on file); internationally used as a fibrate for hypertriglyceridemia/mixed dyslipidemia |
| Predicted New Indication | Rheumatoid Arthritis |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L4 |
| Taiwan Market Status | 未上市 (Not Marketed) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (Data Gap DG002). Based on information available elsewhere in this evidence pack, gemfibrozil is a fibrate-class PPAR-α agonist — its classic pharmacology lowers triglycerides and raises HDL-C, and it is not currently marketed in Taiwan.
The rationale for a link to rheumatoid arthritis is mechanistic rather than direct: PPAR-α activation can inhibit the NF-κB pathway and reduce pro-inflammatory cytokine production, giving fibrates theoretical anti-inflammatory potential. However, the supporting literature in this pack largely concerns bezafibrate (a related but distinct fibrate) in animal arthritis models, not gemfibrozil itself, and the one gemfibrozil-specific study is a small rat adjuvant-arthritis model rather than clinical data. Direct evidence for gemfibrozil in RA is therefore indirect and class-based rather than drug-specific.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30074417 | 2019 | Case Report / animal study | Modern Rheumatology | Combined gemfibrozil (PPAR-α agonist) + reduced-dose steroid gave comparable disease control to full-dose steroid in a rat adjuvant-induced arthritis model |
| 41207105 | 2026 | Preclinical (animal) | International Immunopharmacology | Bezafibrate (pan-PPAR agonist, same drug class as gemfibrozil) attenuated experimental RA via PPAR-γ-dependent modulation of inflammatory pathways |
| 20083653 | 2010 | Preclinical (animal, EAE model) | Journal of Immunology | Nitric oxide/Foxp3 crosstalk in Tregs in an autoimmune (EAE) model — mechanistic, not RA-specific, no gemfibrozil intervention |
| 18039017 | 2007 | Case Report | American Journal of Clinical Dermatology | Review of palmar erythema etiologies; tangential relevance, not a treatment study |
Taiwan Market Information
Currently not marketed in Taiwan — no NDA/許可證 records on file (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. (TFDA label warnings, contraindications, and DDI data are all currently unavailable — Data Gap DG001, Blocking.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for gemfibrozil specifically in rheumatoid arthritis is preclinical/case-report level (L4), with no registered clinical trials, and most supporting literature refers to a related fibrate (bezafibrate) rather than gemfibrozil itself. The mechanistic plausibility (PPAR-α/NF-κB) exists but drug-specific efficacy data is lacking.
To proceed, the following is needed:
- TFDA package insert / warnings & contraindications (DG001, Blocking — currently blocks safety pre-screening)
- Detailed mechanism of action data from DrugBank (DG002)
- Gemfibrozil-specific (not bezafibrate-class) preclinical or clinical evidence in RA
Note: This evidence pack also contains a substantially stronger repurposing signal for the same drug — hypoalphalipoproteinemia/low-HDL (rank 4: Evidence Level L2, decision stage S3, recommendation Proceed with Guardrails), supported by multiple RCTs directly testing gemfibrozil. That candidate warrants separate evaluation as the priority indication for this drug.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.